The Effect of Treating Hearing Loss with Hearing Aids on Plasma Biomarkers of Alzheimer's Disease and Related Dementias.

ABSTRACT:

Background

Promising evidence indicates that treating hearing loss with hearing aids (HAs) could reduce dementia risk. We extend this evidence by investigating the effect of HAs on plasma biomarkers of Alzheimer's disease and related dementias (ADRD).

Methods

We emulated two target trials using observational data from Australian participants of the ASPREE study. Eligible participants had self-reported hearing problems, no past HA use, and were dementia-free. HA prescriptions and frequency of HA use were measured by questionnaire. Phosphorylated-tau181 (pTau181), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and amyloid-β (Aβ) 42/40 were measured after approximately 6-8 years. We estimated the effect of new HA prescription (first target trial) and t

SUBMITTER: Cribb L 

PROVIDER: S-EPMC12668081 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature